MMP-17

MMP-17, also known as membrane-type 4 matrix metalloproteinase (MT4-MMP), is a glycosylphosphatidylinositol (GPI)-anchored matrix metalloproteinase that localizes its catalytic activity to the cell surface and extracellular environment^[1][2]. During development, MMP-17 shows regulated expression in vascular structures, neural tissues, and developing limbs, supporting roles in angiogenesis, neural crest cell migration, and tissue morphogenesis^[3][4]. Mechanistically, MMP-17 participates in extracellular proteolysis and substrate processing, including cleavage of proteins such as osteopontin and pro-TNF, thereby influencing cellular signaling and tissue remodeling pathways^[2][5]. In disease settings, MMP-17 has been implicated in inflammatory cartilage degradation, where genetic or pharmacological evidence links the enzyme to aggrecanolysis under inflammatory conditions^[6][2]. MMP-17 also contributes to vascular homeostasis, and loss-of-function studies have associated reduced MMP-17 activity with altered vascular smooth muscle cell behavior and susceptibility to thoracic aortic aneurysm and dissection phenotypes^[5]. Compared with related membrane-type MMP isoforms, MMP-17 is distinguished by its GPI anchor, limited extracellular matrix substrate repertoire, inability to activate pro-MMP-2, and greater sensitivity to TIMP-1 than TIMP-2, indicating a distinct regulatory and functional profile within the MT-MMP family^[2][7]. For experimental applications, MMP-17 serves as a useful model for investigating cell-surface proteolysis, vascular remodeling, inflammatory tissue damage, and cancer-associated signaling pathways^[2][8].